Fighting cancer: Rocky path for immunotherapies
抗擊癌症，免疫療法真的值得投入嗎？

High hopes that new immunotherapy drugs would prove to have benefits over toxic chemotherapy were dashed by large-scale trials, says David Crow. Pharmaceutical groups are now working on combinations of the immunotherapies and using them with chemo, but some pharma groups have suffered big losses and Wall Street has become sceptical
免疫療法是近年來日益受到青睞的癌症療法，吸引了索羅斯等華爾街金融家的注意。2015年瑞銀全球首席投資官Mark Haefele也公開表示，癌症免疫療法將是下一個最具潛力的長期投資主題之一，預計會帶來極具吸引力的收益。然而在砸下幾十億後換來製藥公司的不斷失敗，已經令華爾街感到懷疑。